TITLE

Sitagliptin, a Selective DPP-4 Inhibitor, Improves Glycemic Control when Added to a Sulfonylurea or to a Sulfonylurea and Metformin in Patients with Type 2 Diabetes

AUTHOR(S)
Hermansen, Kjeld; Kipnes, Mark; Luo, Edmund; Fanurik, Debra; Khatami, Hootan; Stein, Peter P.
PUB. DATE
June 2007
SOURCE
Diabetes;Jun2007 Supplement 1, Vol. 56, pA143
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Efficacy and safety of sitagliptin (SITA) were examined in patients with type 2 diabetes and inadequate glycemic control (A1C 7.5% to 10.5%) on glimepiride (G) alone or G plus metformin (G+MF). After a titration/stabilization period on G (≥4 mg/day) ± MF (≥ 1500 mg/day) and a 2-week placebo (PBO) run-in, 441 patients (mean baseline A1C 8.3%) were randomized to the addition of SITA 100 mg q.d. or PBO for 24 weeks. Of these patients, 212 were on G alone (106 each on SITA or PBO), and 229 on G+MF (116 on SITA, 113 on PBO). The primary endpoint was A1C change from baseline for the entire cohort. After 24 weeks, the addition of SITA reduced A1C by -0.7% (p<0.001) relative to PBO (LS mean change from baseline -0.5% with SITA, +0.3% with PBO) in the entire cohort. Patients on G+MF had a PBO-subtracted A1C change from baseline of -0.9%, and patients on G alone had a PBO-subtracted change from baseline of -0.6%. For the entire cohort, SITA significantly (p<0.001) reduced fasting plasma glucose by 20 mg/dL (1.1 mmol/L) and 2-hour postprandial glucose by 36 mg/dL (2.0 mmol/L) relative to PBO at Week 24. Similar results were observed in the G alone and G+MF strata. HOMA-β was also signficantly (p<0.05) improved with SITA relative to PBO. For the entire cohort, there was a higher incidence of overall adverse experiences (AEs) (60 vs 47%) and drug-related AEs (15 vs 7%) with SITA vs. PBO, with a higher incidence of hypoglycemia AEs (12 vs 2%, respectively) contributing to these differences. At Week 24, body weight was modestly increased with SITA compared with PBO (LS mean change from baseline +0.8 vs -0.4 kg, respectively; p<0.001). In this study, dual or triple therapy with SITA added to G or G+MF improved glycemic control in the fasting and postprandial states. Since co-administration of SITA with MF has an additive effect on active GLP-1 levels (Migoya et al., ADA 2007 submitted), this may have contributed to the greater A1C efficacy observed with triple therapy (SITA with G+MF) compared to dual therapy (SITA with G). The addition of SITA was generally well tolerated; the higher rate of hypoglycemia was consistent with the degree of glycemic improvement and comparable to findings from other add-on to sulfonylurea studies.
ACCESSION #
25820847

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics